Home People

People

The People Running This Company

Sarah London took over as CEO in 2022 after Michael Neidorff's sudden death. The board has been actively refreshed with 7 of 9 directors having tenure under 5 years. Current leadership faces pressure to restore profitability after 2025's earnings collapse.
No Results

Key insight: CEO compensation fell 5% year-over-year despite revenue growth, reflecting pay-for-performance alignment. Equity comprises 80% of CEO pay, heavily weighted toward performance-based RSUs.

What They Get Paid
No Results

Director compensation is reasonable at $325K-$475K for a $28B market cap company. Chairman receives premium for additional responsibilities.

Are They Aligned?
No Results

Skin-in-the-game score: 7/10

CEO London bought $490K worth of shares in August 2025 at $25.50 — demonstrating confidence during the stock's decline. CFO Asher and General Counsel Koster are net buyers through RSU vesting. Director Burdick sold $1.3M in December 2025.

Loading...

Alignment assessment: CEO's $490K purchase is meaningful relative to her $1.47M base salary. However, director selling during the stock's recovery raises questions about confidence in the turnaround.

Board Quality
No Results

Board composition: 7 independent directors, 2 management-affiliated. Median tenure under 5 years after deliberate refresh. Strong healthcare and finance expertise. Audit and Compensation committees chaired by independent directors with relevant backgrounds.

Governance red flags: None material. Related party transaction limited to one executive's family member earning standard compensation.

The Verdict

Grade: B+

Positives:

  • Pay-for-performance working — CEO compensation down 5% despite revenue growth
  • CEO bought $490K shares during crisis — meaningful skin in the game
  • Board refresh successful — 7 of 9 directors tenure under 5 years
  • Strong healthcare and finance expertise on board

Concerns:

  • Director Kenneth Burdick sold $2.6M during stock recovery
  • 2025 earnings collapse raises questions about risk management oversight
  • CEO transition still incomplete 3+ years after Neidorff's death

Upgrade trigger: Sustained earnings recovery above $3.00 adjusted EPS with continued insider buying.

Downgrade trigger: Additional director selling or failure to achieve 2026 guidance of $3.00+ EPS.